Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
Authors
Bröckelmann, PZagadailov, E
Corman, S
Chirikov, V
Johnson, C
Macahilig, C
Seal, B
Dalal, M
Illidge, Timothy M
Affiliation
Department I of Internal Medicine and German Hodgkin Study Group (GHSG), University Hospital of Cologne, CologneIssue Date
2017-09-26
Metadata
Show full item recordAbstract
Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate licensed for the treatment of relapsed/refractory Hodgkin lymphoma (rrHL) following autologous stem cell transplant (ASCT) or at least two prior therapies when ASCT or multiagent chemotherapy is not an option. The objective of this study was to describe real-world outcomes with BV in patients with rrHL considered ASCT ineligible or who refuse ASCT.Citation
Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study. 2017, Eur J HaematolJournal
European Journal of HaematologyDOI
10.1111/ejh.12973PubMed ID
28949403Type
ArticleLanguage
enDescription
Lymphoma Research TeamISSN
1600-0609ae974a485f413a2113503eed53cd6c53
10.1111/ejh.12973
Scopus Count
Collections
Related articles
- Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.
- Authors: Zagadailov EA, Corman S, Chirikov V, Johnson C, Macahilig C, Seal B, Dalal MR, Bröckelmann PJ, Illidge T
- Issue date: 2018 Jun
- Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
- Authors: Pavone V, Mele A, Carlino D, Specchia G, Gaudio F, Perrone T, Mazza P, Palazzo G, Guarini A, Loseto G, Eleonora P, Cascavilla N, Scalzulli P, Melpignano A, Quintana G, Di Renzo N, Tarantini G, Capalbo S
- Issue date: 2018 Oct
- The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
- Authors: Gravanis I, Tzogani K, van Hennik P, de Graeff P, Schmitt P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, Pignatti F
- Issue date: 2016 Jan
- Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.
- Authors: Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A
- Issue date: 2012
- Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
- Authors: Zinzani PL, Pellegrini C, Cantonetti M, Re A, Pinto A, Pavone V, Rigacci L, Celli M, Broccoli A, Argnani L, Pulsoni A
- Issue date: 2015 Dec